ID28005A - 4-benzil piperidina alkilsulfoksida heterolingkar dan penggunaannya sebagai antagonis subtipe reseptor nmda selektif - Google Patents

4-benzil piperidina alkilsulfoksida heterolingkar dan penggunaannya sebagai antagonis subtipe reseptor nmda selektif

Info

Publication number
ID28005A
ID28005A IDW20002514A ID20002514A ID28005A ID 28005 A ID28005 A ID 28005A ID W20002514 A IDW20002514 A ID W20002514A ID 20002514 A ID20002514 A ID 20002514A ID 28005 A ID28005 A ID 28005A
Authority
ID
Indonesia
Prior art keywords
subtipe
heterolingcar
alkylsulfoxide
antagonists
nmda receptor
Prior art date
Application number
IDW20002514A
Other languages
English (en)
Indonesian (id)
Inventor
Jonathan L Wright
Suzanne Ross Kesten
Ravindra B Upsani
Nancy C Lan
Original Assignee
Warner Lambert Company Cs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Company Cs filed Critical Warner Lambert Company Cs
Publication of ID28005A publication Critical patent/ID28005A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW20002514A 1998-06-26 1999-06-25 4-benzil piperidina alkilsulfoksida heterolingkar dan penggunaannya sebagai antagonis subtipe reseptor nmda selektif ID28005A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9091498P 1998-06-26 1998-06-26

Publications (1)

Publication Number Publication Date
ID28005A true ID28005A (id) 2001-05-03

Family

ID=22224939

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002514A ID28005A (id) 1998-06-26 1999-06-25 4-benzil piperidina alkilsulfoksida heterolingkar dan penggunaannya sebagai antagonis subtipe reseptor nmda selektif

Country Status (28)

Country Link
US (1) US6284774B1 (hu)
EP (1) EP1089735B1 (hu)
JP (1) JP2002519322A (hu)
KR (1) KR20010053170A (hu)
CN (1) CN1304307A (hu)
AP (1) AP2000001949A0 (hu)
AT (1) ATE297207T1 (hu)
AU (1) AU769650B2 (hu)
BG (1) BG105082A (hu)
BR (1) BR9911575A (hu)
CA (1) CA2327888A1 (hu)
DE (1) DE69925730T2 (hu)
EA (1) EA200100058A1 (hu)
EE (1) EE200000778A (hu)
ES (1) ES2244201T3 (hu)
HU (1) HUP0102471A2 (hu)
ID (1) ID28005A (hu)
IL (1) IL138949A0 (hu)
IS (1) IS5667A (hu)
NO (1) NO20006482L (hu)
NZ (1) NZ508808A (hu)
OA (1) OA11570A (hu)
PE (1) PE20000728A1 (hu)
PL (1) PL345024A1 (hu)
SK (1) SK19512000A3 (hu)
TR (1) TR200003888T2 (hu)
WO (1) WO2000000197A1 (hu)
ZA (1) ZA200005848B (hu)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) * 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
AP2002002664A0 (en) 2000-04-26 2002-12-31 Warner Lambert Co Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
WO2001092204A1 (en) * 2000-06-01 2001-12-06 Warner-Lambert Company Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
ES2291329T3 (es) * 2000-07-18 2008-03-01 Dainippon Sumitomo Pharma Co., Ltd. Inhibidores de la recaptacion de serotonina.
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
US7217716B2 (en) 2001-02-23 2007-05-15 Merck & Co., Inc. N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
WO2002080928A1 (en) 2001-04-03 2002-10-17 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
CA2381630A1 (en) * 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
SI1409477T1 (sl) 2001-07-24 2009-02-28 Richter Gedeon Nyrt Derivati piperidina kot antagonisti nmda-receptorjev
KR20040066788A (ko) 2001-08-31 2004-07-27 더 락커펠러 유니버시티 프스포다이에스터레이즈 활성 및 뇌에서프스포다이에스터레이즈 1ｂ 매개되는 신호의 조절
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US7157480B2 (en) * 2001-12-11 2007-01-02 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP1845968A2 (en) * 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
JP2009504748A (ja) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
CN103058957A (zh) 2007-06-29 2013-04-24 埃莫里大学 用于神经保护的nmda受体拮抗剂
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
TWI410420B (zh) * 2008-02-05 2013-10-01 Dainippon Sumitomo Pharma Co 苄基哌啶化合物
BRPI0910575A2 (pt) 2008-04-18 2017-06-06 Arizona Board Of Regents A Body Corp Of The State Of Arizona Acting For And Behalf Of The Univ Of Ar métodos para tratar degeneração macular relacionada com a idade, para limitar desenvolvimento de degeneração macular relacionada com a idade, e para identificar compostos para tratar degeneração macular relacionada com a idade, e, composição
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
HUP0900130A3 (en) 2009-03-03 2012-02-28 Richter Gedeon Nyrt Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
KR20120051716A (ko) 2009-08-04 2012-05-22 다이닛본 스미토모 세이야꾸 가부시끼가이샤 벤질피페리딘 화합물
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
MX2014004469A (es) 2011-11-22 2014-08-01 Univ California Metodos y composiciones para tratar inflamacion y lesion isquemica.
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
LT3019167T (lt) 2013-07-12 2021-03-25 Knopp Biosciences Llc Eozinofilų ir (arba) bazofilų padidintų kiekių gydymas
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
CN111372578A (zh) 2017-08-24 2020-07-03 阿达玛斯药物有限责任公司 金刚烷胺组合物、其制备和使用方法
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
WO2020219975A1 (en) * 2019-04-26 2020-10-29 Cytosolve, Inc. Compositions for improving brain health and memory

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792187A (fr) * 1971-12-03 1973-03-30 Sumitomo Chemical Co Nouveaux derives d'alkylamines
DE2845537A1 (de) * 1978-10-19 1980-04-30 Bayer Ag Benzimidazolylcarbamidsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
EP0488959A3 (en) 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
JPH05194505A (ja) * 1991-08-09 1993-08-03 Yoshitomi Pharmaceut Ind Ltd チオフェン化合物
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
ES2128629T3 (es) 1994-10-31 1999-05-16 Merck Patent Gmbh Derivados de bencilpiperidina con afinidad elevada a puntos de enlace de receptores de aminoacidos.
AU5271296A (en) * 1995-04-07 1996-10-23 Novo Nordisk A/S Novel method
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
EP0934314A1 (en) * 1996-10-04 1999-08-11 Novo Nordisk A/S N-substituted azaheterocyclic compounds
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat

Also Published As

Publication number Publication date
EP1089735A1 (en) 2001-04-11
EP1089735A4 (en) 2002-12-18
US6284774B1 (en) 2001-09-04
PL345024A1 (en) 2001-11-19
IS5667A (is) 2000-10-16
ES2244201T3 (es) 2005-12-01
AU4830399A (en) 2000-01-17
TR200003888T2 (tr) 2001-06-21
BG105082A (en) 2001-09-28
BR9911575A (pt) 2001-03-20
NO20006482D0 (no) 2000-12-19
NZ508808A (en) 2002-12-20
DE69925730T2 (de) 2006-03-23
KR20010053170A (ko) 2001-06-25
WO2000000197A1 (en) 2000-01-06
ATE297207T1 (de) 2005-06-15
CN1304307A (zh) 2001-07-18
EE200000778A (et) 2002-04-15
EA200100058A1 (ru) 2001-08-27
JP2002519322A (ja) 2002-07-02
OA11570A (en) 2004-07-01
SK19512000A3 (sk) 2001-08-06
IL138949A0 (en) 2001-11-25
NO20006482L (no) 2000-12-19
CA2327888A1 (en) 2000-01-06
DE69925730D1 (de) 2005-07-14
HUP0102471A2 (hu) 2002-05-29
ZA200005848B (en) 2001-12-18
EP1089735B1 (en) 2005-06-08
AP2000001949A0 (en) 2000-12-31
AU769650B2 (en) 2004-01-29
PE20000728A1 (es) 2000-08-21

Similar Documents

Publication Publication Date Title
ID28005A (id) 4-benzil piperidina alkilsulfoksida heterolingkar dan penggunaannya sebagai antagonis subtipe reseptor nmda selektif
ID30401A (id) Turunan-turunan indol dan penggunaannya sebagai antagonis mcp-1
ID19623A (id) Antagonis reseptor vitronektin
PT1009732E (pt) 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
ATE368659T1 (de) Thrombinrezeptorantagonisten
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
ID19253A (id) Bahan antagonis reseptor vitronektin, pembuatannya dan penggunaannya
ATE357443T1 (de) Dihydrobenzodioxincarbonsäureamid- und ketonderivate als 5-ht4-rezeptorantagonisten
DE69812602D1 (de) Antagonisten des vitronectin-rezeptors
ATE386720T1 (de) Piperidin ccr-3 rezeptor-hemmer
DE69823694D1 (de) Thrombin-rezeptor antagonisten
ID26223A (id) Antagonis reseptor vitronektin
ID22916A (id) Turunan-turunan ergolin dan penggunaannya sebagai antagonis reseptor somatostatin
ID19245A (id) Antagonis reseptor vitronektin, pembuatannya dan pemakaiannya
ID24162A (id) Antagonis-antagonis reseptor vitronektin
ATE286022T1 (de) Naphthalin-carboxamide als tachykinin rezeptorantagonisten
ID22838A (id) Oksazolidina sebagai antagonis 5-ht2a
ID24468A (id) 2-asilaminopropanamina sebagai antagonis reseptor tachykinin
ID28811A (id) Antagonis reseptor vitronektin
ID30484A (id) Turunan 4-heterosikliksulfonamidil 6 metoksi 5 (2 metoksi fenoksi) 2 piridil-pirimidin, pembuatannya dan penggunaan sebagai antagonis reseptor endotelin
ID24309A (id) 2-asilaminopropanamina sebagai antagonis reseptor tachykinin
NO20010620D0 (no) Vitronektinreseptor-antagonister
ID26508A (id) Oksim-oksim tersubstitusi sebagai antagonis-antagonis neurokinin
ID22978A (id) Antagonis reseptor endotelin
HUP0102531A3 (en) Carboxy substituted carboxamide derivatives and their use as tachykinin receptor antagonists